Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Synthetic Glioblastoma Mutated Tumor-specific Peptides Vaccine

Vaccine (Peptide vaccine) · Immune activation, directed at patient-specific tumor-mutated peptides (neoantigens) · developed by Immatics Biotechnologies GmbH

Phase 1 Most advanced trial (none active)
IMTX Developer
1 Registered trials

What is Synthetic Glioblastoma Mutated Tumor-specific Peptides Vaccine?

Synthetic Glioblastoma Mutated Tumor-specific Peptides Vaccine is a personalized peptide-based cancer vaccine made of one or two synthesized patient-specific tumor-mutated peptides. It is designed to stimulate a cytotoxic T-lymphocyte response against tumor cells expressing those mutated antigens, and is studied in glioblastoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine (Peptide vaccine)
Targets
patient-specific tumor-mutated peptides (neoantigens) (antigen)
Mechanism
Immune activation, directed at patient-specific tumor-mutated peptides (neoantigens)
Pathways
cytotoxic T-lymphocyte response
Therapy area
Oncology
Developer
Immatics Biotechnologies GmbH (IMTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02149225 Phase 1 Glioblastoma Completed IMTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Glioblastoma

More from Immatics Biotechnologies GmbH

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the IMTX page.

Follow IMTX, the company behind Synthetic Glioblastoma Mutated Tumor-specific Peptides Vaccine

See IMTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IMTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.